David Mischoulon

TL;DR: The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic Acid (DHA), in mood disorders.

TL;DR: A viewpoint from an international collaboration of academics is presented, in which a context and overview of the current evidence in this emerging field of research is provided, and the future direction of recognition of diet and nutrition as central determinants of both physical and mental health is advocated.

TL;DR: Current evidence supports adjunctive use of SAMe, methylfolate, omega-3, and vitamin D with antidepressants to reduce depressive symptoms.

TL;DR: A number of studies report poorer quality of life in MDD patients compared to controls, and trials comparing the role of newer psychopharmacologic agents in the acute phase of treatment, and the roleof newer psychotherapies in the continuation and maintenance phases of treatment are lacking, to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care.

TL;DR: Overall, SAMe appears to be safe and effective in the treatment of depression, but more research is needed to determine optimal doses and to clarify SAMe's place in the psychopharmacologic armamentarium.